BNIP2 (BCL2 interacting protein 2) is a pro-apoptotic protein that functions as a suppressor of cell survival and regulator of cellular transformation. Primary function: BNIP2 interacts with BCL-2 and promotes apoptotic cell death 1, with its expression directly correlating with chemotherapy sensitivity and favorable prognosis in neuroblastoma 2. Mechanism: BNIP2 contains a BCH (BNIP2 and Cdc42GAP homology) domain that mediates interactions with specific RhoA conformers and the RhoGEF Lbc, inhibiting RhoA-induced cellular transformation 3. BNIP2 also participates in protein complexes regulating myogenic differentiation via Cdon-mediated signaling 4. Disease relevance: BNIP2 expression is downregulated by microRNA miR-20a in colorectal adenocarcinoma, contributing to chemotherapy resistance 5, while estrogen-induced BNIP2 suppression mediates neuroprotective effects in neural cells 1. Elevated BNIP2 expression predicts favorable neuroblastoma outcomes and increased sensitivity to apoptosis-inducing agents 2. Clinical significance: BNIP2 upregulation by prolactin-induced protein enhances breast cancer cell sensitivity to doxorubicin, cyclophosphamide, and paclitaxel, correlating with improved patient survival 6. BNIP2 represents a potential therapeutic target for overcoming chemotherapy resistance in multiple cancer types.